Scarica l'app Stockscreener
0.3719
4.32%
-0.0168
Mereo Biopharma Group Plc Adr Borsa (MREO) Ultime notizie
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - PR Newswire
Mereo BioPharma Group plc Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsMREO - ChartMill
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
MREO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Mereo BioPharma Group plc - Sahm
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma - Chartmill
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Mereo BioPharma Group plc Securities Class Action Lawsuit - Chartmill
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Hold” by Brokerages - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO - Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - ChartMill
MREO Stock Price, Forecast & Analysis | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - Chartmill
Mereo BioPharma Group’s (MREO) “Buy” Rating Reiterated at BTIG Research - Defense World
A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update - Sahm
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift - Sahm
MREO: Setrusumab delivers robust BMD and pain improvements in OI, with key regulatory steps ahead - TradingView — Track All Markets
Mereo BioPharma Group (NASDAQ:MREO) Given New $3.00 Price Target at Needham & Company LLC - Defense World
MREO: Late-stage rare disease pipeline advances with strong data, strategic partnerships, and solid cash runway - TradingView — Track All Markets
Mereo BioPharma updates setrusumab program, extends cash runway - Investing.com
Mereo BioPharma updates setrusumab program, extends cash runway By Investing.com - Investing.com India
Mereo BioPharma Provides Corporate Update - Investing News Network
10 Stocks Under $1 That Will Explode - Insider Monkey
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
Mereo BioPharma Group (NASDAQ:MREO) Given New $1.00 Price Target at BTIG Research - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com UK
United States shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Mereo BioPharma stock price target cut by BTIG to $1 from $6 - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures - Investing.com UK
Ultragenyx stock plummets 43% after setrusumab fails in Phase III trial - Investing.com India
Silver Tumbles 8%; Society Pass Shares Spike Higher - Sahm
Dow Falls Over 100 Points; US Pending Home Sales Rise In November - Sahm
Mereo BioPharma stock plummets after failed Phase 3 trials By Investing.com - Investing.com South Africa
Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com India
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mereo’s setrusumab fails primary endpoint in osteogenesis imperfecta trials By Investing.com - Investing.com India
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):